ClinicalTrials.gg
RecruitingNCT07893093Updated Oct 23, 2026

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or Overweight

A Phase 1 interventional study of ASC36 Injection A, for subcutaneous use and ASC36 Placebo Injection A, for subcutaneous use in Chronic Weight Management, sponsored by Ascletis Pharma (China) Co., Limited. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Ascletis Pharma (China) Co., Limited (part of Ascletis Pharma Inc.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 23, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Two Formulations of ASC36 injection

02

Conditions studied

  • Chronic Weight Management

Browse trials for

Keywords

  • Chronic Weight Management
  • Obesity
  • Amylin receptor
03

In context

Obesity

11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

This study's planned enrollment of 144 is above the median of 67 across 9,027 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Ascletis Pharma (China) Co., Limited is the lead sponsor of 12 studies on the registry; 5 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have provided before initiation of any study-specific procedures.
  2. Male or female participants, non-smokers, between 18 and 65 years of age (both inclusive).
  3. Otherwise healthy participants with obesity ( ≥30 kg/m2) or overweight (BMI ≥27 to \<30 kg/m2).
  4. Female participant is eligible to participate if she is not pregnant, breastfeeding, or planning to breastfeed, and one of the following conditions applies:

    • Is a woman of nonchildbearing potential ( [12 months of amenorrhea with follicle-stimulating hormone level consistent with a postmenopausal state [FSH≥40 mIU/mL)]; or surgically sterile [hysterectomy, bilateral salpingectomy, bilateral oophorectomy, bilateral tubal occlusion/ligation]).
    • Is a and using a highly effective method (see Appendix 1) starting from one month before the first dose and lasting until 6 months or 5 half lives, whichever is longer, after the last dose. WOCBP on hormonal contraceptives should be advised to also use a male condom with spermicide since IMP may reduce the efficacy of hormonal contraceptives

Exclusion criteria

Exclusion Criteria:

  1. Have evidence of any active or chronic disease.
  2. Have obesity traced to a medical cause, suggestive of genetic or syndromic obesity or obesity induced by other endocrinologic disorders, such as hypothyroidism, Cushing syndrome, Prader-Willi syndrome and other conditions.
  3. Have used prescription or drugs that promote weight loss within 3 months prior to the first dose of investigational product.
  4. Have any prior diagnosis of diabetes mellitus (T1DM or T2DM), history of ketoacidosis, or hyperosmolar state/coma.
  5. Presence/history of cardiovascular disease incl. stable/unstable angina, MI, , stroke, cardiac decompensation, clinically significant arrhythmias or conduction disorders, per PI discretion.
  6. Have a lifetime history of suicide attempt.
  7. Participants who have any history of or intolerance to amylin receptor agonists, related compounds, or drugs of similar mechanisms of action (MoA).
  8. Have known liver disease, obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or abnormal liver enzymes as defined as follows at screening.

    • Total > 1.5x (ULN);
    • > 2x ULN;
    • ALT > 2x ULN.
  9. Have an (ECG) abnormality at screening as defined as follows:

    • interval > 450 ms (male) or 470 ms (female)
    • PR (PQ) interval prolongation (> 230 ms)
    • Intermittent second or third-degree AV block, or AV dissociation
    • Right Bundle Branch Block (RBBB), left bundle branch block (LBBB), and QRS interval >120 ms.
    • Elevated resting pulse rate (>100 bpm)
  10. Have poorly controlled high blood pressure per Investigator's judgment during screening:

    i. systolic blood pressure (SBP) ≥160 mmHg

    ii. diastolic blood pressure (DBP) ≥100 mmHg

  11. Have the following lab findings at screening:

    • Calcitonin level ≥50 ng/L at screening.
    • Parathyroid hormone (PTH) level outside the reference range.
    • Vitamin D (25-hydroxycholecalciferol) level \<12 ng/mL.
    • Clinically significant magnesium, total calcium, or calcitriol levels.
  12. Have a presence or history of any disorder affecting calcium metabolism and bone turnover (such as hyperparathyroidism, hypoparathyroidism or Paget´s disease)
  13. Prior treatment with antiresorptive agents for osteoporosis (bisphosphonates or denosumab).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    Section 1 Part 1 (SAD) Cohort 1

    SAD Dose 1 for Formulation A

    Drug: ASC36 Injection A, for subcutaneous use · Drug: ASC36 Placebo Injection A, for subcutaneous use

  • Experimental
    Section 1 Part 1 (SAD) Cohort 2

    SAD Dose 2 for Formulation A

    Drug: ASC36 Injection A, for subcutaneous use · Drug: ASC36 Placebo Injection A, for subcutaneous use

  • Experimental
    Section 1 Part 1 (SAD) Cohort 3

    SAD Dose 3 for Formulation A

    Drug: ASC36 Injection A, for subcutaneous use · Drug: ASC36 Placebo Injection A, for subcutaneous use

  • Experimental
    Section 1 Part 1 (SAD) Cohort 4

    SAD Dose 4 for Formulation A

    Drug: ASC36 Injection A, for subcutaneous use · Drug: ASC36 Placebo Injection A, for subcutaneous use

  • Experimental
    Section 1 Part 2 (MAD) Cohort 1

    MAD Dose 1 for Formulation A

    Drug: ASC36 Injection A, for subcutaneous use · Drug: ASC36 Placebo Injection A, for subcutaneous use

  • Experimental
    Section 1 Part 2 (MAD) Cohort 2

    MAD Dose 2 for Formulation A

    Drug: ASC36 Injection A, for subcutaneous use · Drug: ASC36 Placebo Injection A, for subcutaneous use

  • Experimental
    Section 1 Part 2 (MAD) Cohort 3

    MAD Dose 3 for Formulation A

    Drug: ASC36 Injection A, for subcutaneous use · Drug: ASC36 Placebo Injection A, for subcutaneous use

  • Experimental
    Section 1 Part 2 (MAD) Cohort 4

    MAD Dose 4 for Formulation A

    Drug: ASC36 Injection A, for subcutaneous use · Drug: ASC36 Placebo Injection A, for subcutaneous use

  • Experimental
    Section 2 Part 1 (SAD) Cohort 1

    SAD Dose 1 for Formulation B

    Drug: ASC36 Injection B, for subcutaneous use · Drug: ASC36 Placebo Injection B, for subcutaneous use

  • Experimental
    Section 2 Part 1 (SAD) Cohort 2

    SAD Dose 2 for Formulation B

    Drug: ASC36 Injection B, for subcutaneous use · Drug: ASC36 Placebo Injection B, for subcutaneous use

  • Experimental
    Section 2 Part 1 (SAD) Cohort 3

    SAD Dose 3 for Formulation B

    Drug: ASC36 Injection B, for subcutaneous use · Drug: ASC36 Placebo Injection B, for subcutaneous use

  • Experimental
    Section 2 Part 1 (SAD) Cohort 4

    SAD Dose 4 for Formulation B

    Drug: ASC36 Injection B, for subcutaneous use · Drug: ASC36 Placebo Injection B, for subcutaneous use

  • Experimental
    Section 2 Part 2 (MAD) Cohort 1

    MAD Dose 1 for Formulation B

    Drug: ASC36 Injection B, for subcutaneous use · Drug: ASC36 Placebo Injection B, for subcutaneous use

  • Experimental
    Section 2 Part 2 (MAD) Cohort 2

    MAD Dose 2 for Formulation B

    Drug: ASC36 Injection B, for subcutaneous use · Drug: ASC36 Placebo Injection B, for subcutaneous use

  • Experimental
    Section 2 Part 2 (MAD) Cohort 3

    MAD Dose 3 for Formulation B

    Drug: ASC36 Injection B, for subcutaneous use · Drug: ASC36 Placebo Injection B, for subcutaneous use

  • Experimental
    Section 2 Part 2 (MAD) Cohort 4

    MAD Dose 4 for Formulation B

    Drug: ASC36 Injection B, for subcutaneous use · Drug: ASC36 Placebo Injection B, for subcutaneous use

Interventions

  • DrugASC36 Injection A, for subcutaneous use

    ASC36 Injection A is an investigational formulation of ASC36 administered by subcutaneous injection.

  • DrugASC36 Placebo Injection A, for subcutaneous use

    ASC36 Placebo Injection A is an placebo injection matching ASC36 Injection A.

  • DrugASC36 Injection B, for subcutaneous use

    ASC36 Injection B is an investigational formulation of ASC36 administered by subcutaneous injection.

  • DrugASC36 Placebo Injection B, for subcutaneous use

    ASC36 Placebo Injection B is an placebo injection matching ASC36 Injection B.

06

What researchers measure

Primary outcomes

  1. Adverse Events

    A summary of AEs, SAEs, and other non-serious adverse events following single SC doses of ASC36 injection

    Time frame: From baseline to the end of treatment (up to 16 weeks or Day 113)

  2. Adverse Events

    A summary of AEs, SAEs, and other non-serious adverse events following multiple SC doses of ASC36 injection

    Time frame: From baseline to the end of treatment (up to 20 weeks or Day 141)

Secondary outcomes

  1. Cmax of ASC36 Injection

    Evaluate the peak plasma concentration of ASC36 Injection

    Time frame: From baseline to the end of treatment (up to 20 weeks or Day 141)

  2. Tmax of ASC36 Injection

    Evaluate the time to reach peak plasma concentration of ASC36 Injection

    Time frame: From baseline to the end of treatment (up to 20 weeks or Day 141)

  3. AUC of ASC36 Injection

    Evaluate the area under the plasma concentration-time curve of ASC36 Injection

    Time frame: From baseline to the end of treatment (up to 20 weeks or Day 141)

  4. Half-life of ASC36 Injection

    Evaluate the time required for the plasma concentration of ASC36 to decrease by 50%

    Time frame: From baseline to the end of treatment (up to 20 weeks or Day 141)

  5. Percent Change From Baseline in Body Weight

    Percent Change From Baseline in Body Weight

    Time frame: From baseline to the end of treatment (up to 20 weeks or Day 141)

  6. Percent Change From Baseline in Waist Circumference

    Percent Change From Baseline in Waist Circumference

    Time frame: From baseline to the end of treatment (up to 20 weeks or Day 141)

  7. Percent Change From Baseline in BMI

    Percent Change From Baseline in BMI

    Time frame: From baseline to the end of treatment (up to 20 weeks or Day 141)

  8. Immunogenicity of ASC36 Injections

    Incidence and prevalence of treatment-emergent antidrug antibodies against ASC36 after SC doses of ASC36 injection

    Time frame: From baseline to the end of treatment (up to 20 weeks or Day 141)

07

Study locations

2 of 2 sites recruiting
  • Ascletis Clinical Site
    San Antonio, Texas 78232, United States
    Recruiting
  • Ascletis Clinical Site
    Salt Lake City, Utah 84124, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.

Of 336 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 9 months is close to that.

Counting every sponsor, half of 441 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2026
First posted
Oct 23, 2026
StartActual
Sep 28, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07893093
Responsible party
Sponsor
First posted
Oct 23, 2026
Start date
Sep 28, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Ascletis Recruiting
Contact
clinicaltrials@ascletis.com
+1 2068073688

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion